Preventing cancer without killing cells

NewsGuard 100/100 Score

Inducing senescence in aged cells may be sufficient to guard against spontaneous cancer development, according to a paper published online this week in EMBO reports.

It was previously unknown whether cellular senescence or programmed cell death - apoptosis - was the more important safeguard mechanism for suppressing tumours arising from dysfunctional telomeres.

Aged cells have abnormal chromosomes with dysfunctional telomeres - shorter ends - that can promote tumorigenesis in the absence of the tumour suppressor p53, and may be related to the higher incidence of cancer in older individuals. However, in the presence of p53, dysfunctional telomeres can induce a permanent arrest of cell growth, known as senescence. Sandy Chang and colleagues studied mutant mice with dysfunctional telomeres and copies of the p53 gene that cannot initiate p53-dependent apoptosis but can execute p53-mediated senescence.

The authors found that activating the senescence pathway was sufficient to suppress spontaneous tumorigenesis. Their findings suggest that, by halting cellular proliferation, p53-mediated senescence may act as an important tumour suppressor mechanism in aged cells.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery